PMC6752199_01
Identification of EGFR delE709_T710insD (del 18) mutation in exon 18 from lung cancer tumor biopsy.
OTT-12-7399-g0001.jpg
PMC6752199_01_OTT-12-7399-g0001.jpg
F0001
ALK (Figure 1), however, there were no recommended targeted drugs for this mutation. After close surveillance for 15 months, the brain magnetic resonance imaging (MRI) showed a lesion suspected for metastasis in the left temporal lobe of the brain (Figure 2B, a) which was subsequently verified by PET-CT.
Summary of treatment and monitoring tumor response. (A) Various interventions that the patient received. Arrowheads indicate time points for each intervention. (B) Brain magnetic resonance imaging (MRI) 15 months after surgery and chemotherapy (a), when the brain metastasis were first diagnosed and it was on progression at 27 months (b). The metastasis in the brain had almost disappeared after afatinib had been taken for 8 months (c), and it achieved stable state until 48 months (21 months after initially taking afatinib) (d).
OTT-12-7399-g0002.jpg
PMC6752199_01_OTT-12-7399-g0002.jpg
F0002
ALK (Figure 1), however, there were no recommended targeted drugs for this mutation. After close surveillance for 15 months, the brain magnetic resonance imaging (MRI) showed a lesion suspected for metastasis in the left temporal lobe of the brain (Figure 2B, a) which was subsequently verified by PET-CT. However, the brain metastasis progressed again after 1 year, validated by MRI (Figure 2B, b). The brain metastasis shrunk significantly after 3 months and almost disappeared after 8 months, confirmed by MRI (Figure 2B, c). The patient is alive 21 months from initially taking afatinib, now with stable disease (Figures 2B, d and 3).
A metastasis appeared in the right lung on the chest computed tomography image obtained at 38 months and achieved stable disease after the use of SBRT and afatinib until 48 months.
OTT-12-7399-g0003.jpg
PMC6752199_01_OTT-12-7399-g0003.jpg
F0003
The patient is alive 21 months from initially taking afatinib, now with stable disease (Figures 2B, d and 3).